Table II.
Change From Baseline (SD) in Mean Sitting Systolic Blood Pressure/Mean Sitting Diastolic Blood Pressure (mm Hg) at the End of Study 1 in Patients With Stage 1 and Stage 2 Hypertension*
| Stage 1 Hypertension | |||||
|---|---|---|---|---|---|
| Amlodipine Dose, mg | Valsartan Dose, mg | ||||
| 0 | 40 | 80 | 160 | 320 | |
| 0 | −6.4 (10.4)/−8.4 (7.5) | −8.8 (11.8)/−9.1 (8.4) | −11.9 (11.8)/−9.8 (6.4) | −8.8 (14.2)/−11.2 (8.1) | −11.9 (11.6)/−12.6 (7.7) |
| 2.5 | −9.9 (11.4)/−8.9 (7.3) | −11.6 (9.0)/−11.2 (7.5) | −11.1 (10.2)/−12.5 (7.0) | −12.3 (11.3)/−13.0 (5.6) | −16.0 (8.7)/−14.1 (8.5) |
| 5 | −12.1 (10.1)/−10.6 (6.7) | −15.9 (9.4)/−14.7 (7.5) | −16.9 (13.1)/−13.9 (6.8) | −14.6 (15.0)/−14.2 (8.6) | −16.4 (9.7)/−15.0 (6.4) |
| Stage 2 Hypertension | |||||
| Amlodipine Dose, mg | Valsartan Dose, mg | ||||
| 0 | 40 | 80 | 160 | 320 | |
| 0 | −5.9 (15.2)/−4.7 (7.5) | −14.1 (16.7)/−10.4 (9.3) | −13.9 (16.7)/−9.3 (7.2) | −19.8 (13.1)/−10.6 (7.6) | −19.8 (14.0)/−13.6 (7.3) |
| 2.5 | −15.2 (15.2)/−9.3 (7.6) | −18.4 (11.9)/−10.1 (7.4) | −20.6 (15.0)/−13.6 (6.9) | −19.3 (14.5)/−13.0 (8.9) | −19.4 (14.7)/−13.7 (7.3) |
| 5 | −17.5 (13.0)/−11.6 (7.0) | −22.3 (12.0)/−14.2 (6.1) | −24.2 (13.1)/−14.6 (8.0) | −23.2 (11.6)/−13.9 (6.6) | −28.5 (10.7)/−16.5 (6.0) |
| *The number of patients in each treatment group ranged from 53 to 65 in the stage 1 hypertension subgroup and from 62 to 74 in the stage 2 hypertension subgroup. | |||||